Instalab
logoInstalab

Factor XI Activity

Blood Test
Find a clotting-factor problem routine clotting tests can miss after unexplained clots, young stroke, or surgery-related bleeding.
4.8 (3,863 reviews)
Tested by Quest Diagnostics
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get blood drawn
At home or at 2,000+ patient service centers
Get results
Explained with clear next steps, no medical jargon

Should you take a Factor XI Activity test?

This test is most useful if any of these apply to you.

From a Bleeding-Prone Family
Relatives bleed heavily after surgery or dental work, and you want to check for a clotting-protein shortfall.
Under 55 With a Clot or Stroke
A clot or stroke came early, and routine PT and aPTT did not explain it.
Bleeding More Than Expected
You bruised easily or bled heavily after surgery, dental work, childbirth, or injury.
Mapping Your Clot Risk
You want one more piece of your stroke and clot-risk picture beyond a standard coagulation panel.

About Factor XI Activity

Here is the strange thing about this protein: people born with less of it tend to have fewer strokes from blocked blood vessels and fewer deep vein clots, and they rarely trade that for severe spontaneous bleeding. That is why Factor XI drugs exist: they try to lower clot risk without copying the bleeding risk of older anticoagulants.

Your Factor XI activity can shift risk in both directions. Too much tilts you toward strokes and clots. Too little usually causes only mild bleeding, mostly after surgery, dental work, childbirth, or injury.

What Factor XI Does in Your Blood

Factor XI is a clotting protein your liver makes and releases into the blood. It circulates in an inactive form. When a clot starts to form, other clotting signals switch it on, and it speeds up the chain reaction that reinforces the clot.

What makes it unusual is timing. It is not needed to start most clots, but it helps amplify them and make them hold. It also slows your body's clot-dissolving system. That matters most at moist surfaces like the mouth, nose, and urinary tract, where clots break down fast. That is why bleeding from a shortfall often shows up at those sites.

Strokes and Blood Clots

Higher Factor XI activity tracks with more clots. In adults under 55 worked up for unexplained clotting whose prothrombin time and aPTT were both normal, those with elevated Factor XI activity were about five times as likely to have had a stroke or mini-stroke, and about four times as likely to have had a vein clot.

Genetic studies push this from association toward cause, but they often use plasma Factor XI levels rather than this exact activity assay. One analysis used inherited differences tied to Factor XI levels in 16,169 people and then tested stroke outcomes in much larger datasets; genetically higher Factor XI was tied to about two and a half times the odds of ischemic stroke. The strongest signal was for cardioembolic stroke, the type often linked to clots from the heart. In a DVT study, a high Factor XI result after anticoagulants were stopped was tied to about twice the odds of DVT; when it stayed high three months later, the odds were about five times higher.

If you have had a clot or stroke and your routine coagulation panel came back clean, this is one of the few numbers that can still be off.

Heart Disease and Death

In people already living with coronary artery disease, higher Factor XI activity has lined up with higher death rates. A related signal shows up when the active form, FXIa, is detectable in the blood: in one small stable heart-disease cohort, those patients were more than six times as likely to have a heart attack, stroke, systemic clot, or cardiovascular death over long follow-up. FXIa is not the same thing as a Factor XI activity result, but it points to the same clot-amplifying system being turned on.

Across 3,170 people sent for coronary angiography, the pattern was not straight. Both low and high Factor XI activity tracked with higher death rates overall, while people without coronary disease showed a U-shaped curve and people with coronary disease had rising risk as Factor XI rose. That is an early sign this is not a simple lower-is-always-better number.

The Bleeding Side: Factor XI Deficiency

Being low on Factor XI causes a mild-to-moderate bleeding tendency, and here the biology turns counterintuitive. The level does not reliably predict who bleeds. Some people with almost no Factor XI sail through surgery, while others with partial deficiency bleed heavily.

When bleeding happens, it usually follows trauma, childbirth, dental work, or an operation rather than appearing on its own, and it clusters at moist sites like the mouth, nose, and urinary tract. In a 2025 Southern Italian cohort, about a third of people with congenital deficiency had bleeding symptoms, so a personal history of bleeding tells you more than the number does.

The deficiency is far more common in people of Ashkenazi Jewish descent, and in a few other groups with shared ancestry such as French Basques, where a handful of inherited variants account for many cases.

A Possible Heart Failure Signal

A newer thread complicates the low-is-protective story. In roughly 4,500 community-dwelling adults, lower plasma Factor XI level went with more heart failure, not less. Each halving of the level was tied to about a third higher risk, strongest in people older than 75, along with worse measures of how the heart relaxes and fills. This was a protein-level study, not a Factor XI activity cutoff.

So how can low Factor XI protect against clots yet possibly go with more heart failure? This is not a good-number, bad-number marker. It looks like Factor XI does one job in clotting and, separately, may do something in the heart muscle itself. That heart-muscle mechanism has been seen mainly in animal studies so far. A 2025 human genetic study found no causal link between genetically lower Factor XI and heart failure or measures of cardiac function, so the observational heart failure signal may reflect other factors rather than Factor XI itself. The mortality link also depends on context: in people without coronary disease the risk curve is U-shaped, while in those with coronary disease higher activity tracks with worse outcomes. Different settings, different risks.

Why a Normal Clotting Panel Can Miss It

The routine screen for this part of clotting is the aPTT (activated partial thromboplastin time), and many people assume a normal aPTT rules out a Factor XI problem. It does not. Children and adults with mild deficiency can have a normal aPTT; in one small pediatric series, four of seven confirmed cases screened normal.

The miss runs both ways. Among younger stroke and mini-stroke patients whose prothrombin time and aPTT were both normal, more than one in five had elevated Factor XI activity. A standard panel is a blunt screen. Measuring Factor XI activity directly is what reads this protein.

When Results Can Be Misleading

  • Fresh clot or recent clotting event: Factor XI activity can be higher during an acute vein clot than it is a year later. A sample drawn near an active clot can make your baseline look higher than it is.
  • Liver disease: because the liver makes Factor XI, cirrhosis can lower it as liver function worsens. That fall reflects liver function, not an inherited bleeding trait.
  • Anticoagulants, clot-dissolving drugs, or recent plasma treatment: warfarin, heparin, direct oral anticoagulants, clot-dissolving drugs, plasma, and factor replacement can distort the result or temporarily change the activity being measured.
  • Investigational Factor XI inhibitors: drugs that block Factor XI or FXIa can make functional assays read low, so the number may reflect the drug more than your baseline.
  • Sample handling: this is a plasma clotting assay. Underfilled citrate tubes, clotted samples, platelet contamination, or thawed-in-transit samples can give bad results.
  • Ordinary day-to-day variation: a single value is a snapshot. If the result will change a clotting or surgery decision, repeat it when you are well.

Why One Reading Isn't Enough

Because a fresh clot, liver stress, anticoagulants, and sample handling can all move Factor XI activity, a single value can mislead in either direction. Two consistent readings taken when the context is clean are more trustworthy than one surprise.

What to Do With an Out-of-Pattern Result

A high result matters most alongside a personal or family history of clots or stroke. That combination is worth taking to a hematologist, who can fold it into a broader clotting workup and sharpen your cardiovascular prevention. A high Factor XI result is not, by itself, a reason to take an anticoagulant.

A low result matters most before surgery, childbirth, dental work, or if you bleed easily. Pair it with your prothrombin time, a mixing study to rule out an inhibitor, and, when available, a thrombin generation assay. A thrombin generation assay watches a blood sample make thrombin. Thrombin is an enzyme that helps build a clot. This may predict bleeding better than the Factor XI number does. The most useful companion to the level is a clear account of how you have bled in the past.

What Moves This Biomarker

Evidence-backed interventions that affect your Factor XI Activity level

Decrease
Factor XI antisense oligonucleotides (investigational, e.g., IONIS-FXIRx)
These investigational drugs cut how much Factor XI your liver makes, lowering measured Factor XI activity over several weeks. In a knee-replacement trial, the higher-dose regimen cut postoperative vein clots from about 30% with enoxaparin to about 4%, with fewer clinically relevant bleeding events, but the bleeding comparison was small. None are approved, so this is not something you can take today.
MedicationStrong Evidence
Decrease
Anti-Factor XI monoclonal antibodies (investigational, e.g., abelacimab)
Abelacimab-like antibodies bind Factor XI and block its activation, lowering functional Factor XI activity quickly. In one knee-replacement trial, higher doses lowered postoperative vein clots more than enoxaparin, with rare bleeding, but these drugs are not approved. The antibody can interfere with activity assays, so the measured number may not mirror your true baseline while on the drug.
MedicationStrong Evidence
Decrease
Small-molecule FXIa inhibitors (investigational, e.g., asundexian, milvexian)
These pills block the active form of the protein rather than lowering how much protein is present, so they reduce Factor XI-related clotting activity on functional testing without necessarily lowering antigen levels. Orthopedic-surgery trials looked promising, but stroke and atrial-fibrillation trials have been mixed, and one large atrial-fibrillation trial found more strokes with asundexian than apixaban despite less bleeding. None are approved for prevention.
MedicationStrong Evidence
Increase
Fresh frozen plasma infusion for selected Factor XI deficiency management
Fresh frozen plasma supplies Factor XI directly and temporarily raises plasma Factor XI activity. It is used selectively for major bleeding or high-risk procedures in people with deficiency, because many low-Factor XI patients do not bleed and plasma can cause volume overload.
ProcedureModerate Evidence

Frequently Asked Questions

References

54 studies
  1. J. Emsley, P. Mcewan, D. GailaniBlood2010
  2. B. Bouma, J. MeijersCurrent Opinion in Hematology2000
  3. Ke Zhang, L. Qin, Fei Xu, Longying Ye, Mengzhen Wen, Jingye Pan, Lihong Yang, Mingshan Wang, Hai-xiao XieOrphanet Journal of Rare Diseases2024
  4. A. Greco, C. Laudani, M. Spagnolo, F. Agnello, D. Faro, S. Finocchiaro, M. Legnazzi, M. S. Mauro, P. M. Mazzone, Giovanni Occhipinti, C. Rochira, Lorenzo Scalia, D. CapodannoCirculation2023